Hyperuricemia predicts poor prognosis of patients with cervical cancer

Cuihong Li; Yufeng Li; Na Su; Qiongna Liu; Chunxiang Chai

doi:10.18632/oncotarget.23589

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Hyperuricemia predicts poor prognosis of patients with cervical cancer

Cuihong Li, Yufeng Li, Na Su, Qiongna Liu and Chunxiang Chai _

PDF | HTML | How to cite

DOI pending

Metrics: PDF 435 views | HTML 856 views | ?

Abstract

Cuihong Li1, Yufeng Li2, Na Su2, Qiongna Liu3 and Chunxiang Chai4

1Department of Gynaecology and Obstetrics, Yidu Central Hospital of Weifang, Weifang 261000, China

2Department of Oncology, People’s Hospital of Rizhao, Rizhao 276800, China

3Department of Obstetrics and Gynecology, Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an 223001, China

4Department of Rheumatology and Immunology, The Affiliated Hospital of Weifang Medical University, Weifang 261000, China

Correspondence to:

Chunxiang Chai, email: [email protected]

Yufeng Li, email: [email protected]

Keywords: cervical cancer; uric acid; hyperuricemia; prognosis

Received: August 18, 2017 Accepted: December 11, 2017 Published: January 02, 2018

ABSTRACT

Previous studies have suggested that hyperuricemia plays an important role in cancer initiation and progression; however, little is known about the role of hyperuricemia in the prognosis of cervical cancer. The aim of this study was to evaluate the association between hyperuricemia and cervical cancer by conducting a retrospective cohort study. 50 cervical cancer patients with hyperuricemia were randomly selected and 1:1 age-matched to 50 normouricemia patients with cervical cancer. We used the Kaplan–Meier survival analysis to determine the overall survival of patients with cervical cancer. Cox regression analysis was also adopted to estimate the role of hyperuricemia in cervical cancer prognosis primarily adjusted by age, tumor stage, status of histological grade, lymph node involvement, and histopathological subtype. The Kaplan–Meier analysis showed patients with hyperuricemia had poorer overall survival than those with normouricemia (P = 0.0086). The univariate and multivariate Cox analyses both showed that hyperuricemia was negatively associated with the overall survival of patients with cervical cancer. Our study suggests that hyperuricemia is related to poor prognosis of patients with cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23589

Publication Alerts

Research Papers:

Hyperuricemia predicts poor prognosis of patients with cervical cancer

Abstract